Title: Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation
Authors: Miles, LA
Crespi, GAN
Doughty, L
Parker, MW
Issue Year: 2013
Publisher NATURE PUBLISHING GROUP
Series SCIENTIFIC REPORTS: 3(): -
Abstract Bapineuzumab is a humanized antibody developed by Pfizer and Johnson & Johnson targeting the amyloid (A beta) plaques that underlie Alzheimer's disease neuropathology. Here we report the crystal structure of a Fab-A beta peptide complex that reveals Bapineuzumab surprisingly captures A beta in a monomeric helical conformation at the N-terminus. Microscale thermophoresis suggests that the Fab binds soluble A beta(1-40) with a K-D of 89 (+/- 9) nM. The structure explains the antibody's exquisite selectivity for particular A beta species and why it cannot recognize N-terminally modified or truncated A beta peptides.
URI: https://publications.svi.edu.au/publications/1722
Other Identifiers 10.1038/srep01302
Publication type Article
Grant ID GNT1021645; GNT1021935
Find it online http://www.nature.com/srep/2013/130218/srep01302/pdf/srep01302.pdf